Chiesi to buy KalVista in $1.9B deal for rare disease drug
BioPharma Dive
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma s interest in new and emerging oral therapies for hereditary angioedema.
pharminent
April 29, 2026 (Last updated: April 30, 2026)
BioPharma Dive
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma s interest in new and emerging oral therapies for hereditary angioedema.